Silvia Giannini, Ph.D. Email & Phone Number

Boston, Ma, Us

Work focused on the development of iPSC-derived platelet like cells for treating bleeding, autoimmune and malignant disorders.Lead the in vivo pharmacology team supporting the advancement of projects from early discovery to clinical evaluation. Design and execute PK, PD, biodistribution and efficacy studies to test lead drug candidates.Develop mouse models of hemostatic, autoimmune and malignant disorders.

Cambridge, Ma

Brigham And Women'S Hospital/Harvard Medical School, Boston

Group leader managing a laboratory focused on evaluating the potential application of glycanmodifications as an avenue to regulate hematopoiesis in hematologicconditions.Relevant publications: 1. Giannini S, Lee-Sundlov M, Rivadeneyra L, Di Buduo CA, Burns R, Lau JT, Falet H, Balduini A, Hoffmeister KM. β4GALT1 controls β1 integrin function to govern thrombopoiesis and hematopoietic stem cell homeostasis. Nature Communications, 2020.2. Di Buduo CA, Giannini S, Abbonante V, Rosti V, Hoffmeister K, Balduini A. Increased β4GALT1 expression associates with platelet surface galactosylation and thrombopoietin plasma levels in MPNs. Blood, 2020.3. Giannini S, Falet H, Hoffmeister KM. Platelet Glycobiology and the Control of PlateletFunction and Lifespan. In: Michelson AD, Cattaneo M, Frelinger L, Newman P eds. Platelets, 4th Edition. Amsterdam: Elsevier Academic Press; 2019.

Brigham And Women'S Hospital/Harvard Medical School

Research focused in understanding glycan-mediated mechanisms controlling blood cell production by regulating cell adhesion and migration with the purpose to develop new strategies to treat patients with inpaired hematopoiesis due to congenital disorders or cancer treatment. Awards:• R01 HL 134829, National Institutes of Health (NIH) - The role of Glycans in thrombopoiesis 2017-2021• Bridge Grant Award. American Society of Hematology (ASH). 2017-2018• Fund to Sustain Research. Brigham and Women's Hospital Biomedical Research Institute. 2016-2017• Chair’s Research Award. Research Performance Incentive Program. Brigham and Women’s Hospital, Boston. 2017Relevant publications: 1. Elf et al. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016.2. Fischer et al. Testing the efficacy of Contrast Enhanced Ultrasound in detecting transplant rejection using a murine model of heart transplantation. Am J Transplant. 2017.

Brigham And Women'S Hospital/Harvard Medical School

Worked within Dr. Karin Hoffmeister and Dr. Hervé Falet’s laboratories which focus on understanding the mechanisms of platelet production and clearanceRelevant publications:1. Bender M*, Giannini S*, et al. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood. 2015. *Co-first authorship2. Jurak Begonja A, et al. FlnA binding to PACSIN2 F-BAR domain regulates membrane tubulation in megakaryocytes and platelets. Blood. 2015; 126:80-8.3. Grozovsky Ret al. Regulating billions of blood platelets: glycans and beyond. Blood. 2015; 126:1877-84. Review.4. Grozovsky R et al. Novel mechanisms of platelet clearance and thrombopoietin regulation. Curr Opin Hematol 2015; 22:445-51. Review.

Perugia, Italy

Work focused on studying the mechanisms of platelet activation and its contribution to ischemic cardiovascular disease.• Studied the role of platelet-derived matrix metallo-proteinase 2 (MMP2) and CD40L in facilitating platelet and endothelial cell activation• Demonstrated that viral infection but not antiretroviral therapy, is responsible for the endothelial cell dysfunction observed in patients with chronic HIV infection• Proved that hyperglycemia-induced platelet activation is reversed by a nitric oxide-donating agent but not by aspirin in patients with type-2 diabetesRelevant publications:1. Falcinelli et al. Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of Inhibition by aspirin. Br J Haematol. 2007.2. Francisci et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS. 2009.3. Momi et al. Loss of matrix metalloproteinase-2 (MMP-2) in platelets reduces arterial thrombosis in vivo. J Exp Med. 2009.4. Gresele et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care. 20105. Falcinelli et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thromb Haemost. 2013.

Doctor Of Philosophy (Phd), Biology And Molecular Biotechnology

Worked within Dr. Paolo Gresele’s laboratory on the study of rare congenital and acquired hemostatic disorders • Developed flow cytometric.

Master Of Science (Ms), Biological Sciences

Thesis: Priming of platelet activation by human β-N-acetyl exosaminidase